*Toulouse and Geneva, March 14th, 2017*

# Genkyotex to participate in the 1st Annual H.C. Wainwright NASH Investor Conference in New York, on April 3rd, 2017

## *Elias Papatheodorou, CEO of Genkyotex, is scheduled to present the company at 8am EST*

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that its CEO will be attending the 1st annual H.C. Wainwright NASH (*Nonalcoholic Steatohepatitis*) investor conference, to be held in New York on April 3rd, 2017 at the St. Regis hotel (Versailles Room).

This first edition of the conference will gather 16 European and US biotech companies, active in the NASH therapeutic field, as well as renowned NASH key opinion leaders. NASH is a liver disease, involving accumulation of fat, inflammation and injury to liver cells. The condition leads to higher risks of developing cirrhosis and liver cancer.

On this occasion, Elias Papatheodorou, CEO, is scheduled to present Genkyotex at 8am EST, focusing on the drug candidate GKT831 which targets fibrotic indications. GKT831 is expected to enter a phase II clinical trial in Primary Biliary Cholangitis (PBC) in H1 2017, and has the potential to address other fibrotic liver diseases including NASH.

### About Genkyotex

*Genkyotex is the leading biopharmaceutical company in NOX therapies. Listed on the Euronext Paris and Euronext Brussels markets, Genkyotex is established in France and, via its GenKyoTex Suisse SA subsidiary, in Switzerland. A leader in NOX therapies, its unique therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration.*

*Genkyotex's platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes. Genkyotex is developing a pipeline of first-in-class product candidates targeting one or multiple NOX enzymes. The lead product candidate, GKT831, a NOX1 and NOX4 inhibitor is expected to enter a phase II clinical trial in primary biliary cholangitis (PBC, a fibrotic orphan disease) during the first half of 2017. This product candidate may also be active in other fibrotic indications. Its second product candidate, GKT771, is a NOX1 inhibitor targeting multiple pathways in angiogenesis, pain processing, and inflammation, and should enter a phase I clinical study during the second half of 2017.*

*Genkyotex also has a versatile platform, Vaxiclase, that is particularly well-suited to the development of various immunotherapies. A partnership covering the use of Vaxiclase as an antigen per se (GTL003) has been established with Serum Institute of India Ltd (Serum Institute), the world's largest producer of vaccine doses. This agreement covers territories outside the United States and Europe, and could generate up to $57 million in revenues for Genkyotex, before royalties on sales. It will enable Serum Institute to develop acellular multivalent combination vaccines against a variety of infectious diseases, including whooping cough. The last*

*preclinical milestone foreseen in the agreement was reached in November 2016, opening the path to formal preclinical testing prior to potential clinical development and subsequent commercialization.*

***For further information, please go to*** www.genkyotex.com

GKTX
LISTED
EURONEXT

ELIGIBLE
PEA
PME

***Disclaimer***

*This press release and the information it contains does not constitute an offer or solicitation to buy, sell or hold Genkyotex shares in any country, in particular any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or other qualification under the securities laws of any such jurisdiction.*

*This press release may contain forward-looking statements by the company with respect to its objectives. Such statements are based upon the current beliefs, estimates and expectations of Genkyotex's management and are subject to risks and uncertainties such as the company's ability to implement its chosen strategy, customer market trends, changes in technologies and in the company's competitive environment, changes in regulations, clinical or industrial risks and all risks linked to the company's growth. These factors as well as other risks and uncertainties may prevent the company from achieving the objectives outlined in the press release and actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include uncertainties involved in the development of Genkyotex's products, which may not succeed, or in the delivery of Genkyotex's products marketing authorizations by the relevant regulatory authorities and, in general, any factor that could affects Genkyotex's capacity to commercialize the products it develops. No guarantee is given on forward-looking statements which are subject to a number of risks, notably those described in the registration document filed with the French Markets Authority (the AMF) on 1 April 2015 under number R.15-015, as updated in the Document E filed with the AMF on 31 January 2017 under number E.17-004, and those linked to changes in economic conditions, the financial markets, or the markets on which Genkyotex is present. Genkyotex products are currently used for clinical trials only and are not otherwise available for distribution or sale.*


| EUROPE | MEDIA |
|---|---|
| **NewCap**<br>Dušan Orešanský, Tristan Roquet Montégon and Emmanuel Huynh<br>+33 1 44 71 94 92<br>genkyotex@newcap.eu | **ALIZE RP**<br>Caroline Carmagnol, Simon Derbanne and Laetitia Abbar<br>+33 6 64 18 99 59<br>genkyotex@alizerp.com |